Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dapoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 12/20 | 0.56 |
| ▸ | HTR1D | P28221 | 4/20 | 0.52 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapoxetine SCHEMBL9292059 | 1.00 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL27937194 | 1.00 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL29352095 | 1.00 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL27518070 | 1.00 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL28224802 | 0.99 | HTR1B (0.55) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL30600097 | 0.99 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL29387056 | 0.99 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL3672581 | 0.99 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL3679561 | 0.99 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL34479 | 0.99 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115792062-B | Detection method suitable for triethylamine residual quantity | 山东创新药物研发有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119901216-A | Device and method for detecting thickness of dapoxetine hydrochloride tablet coating | 瑞宏(山东)医药科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-118955306-B | Improved process method of dapoxetine hydrochloride | 广州市桐晖药业有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-118955306-A | Improved process method of dapoxetine hydrochloride | 广州市桐晖药业有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118961912-A | Separation detection method for known impurities in dapoxetine hydrochloride intermediate PM2 | 北京悦康科创医药科技股份有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118924815-A | Pharmaceutical composition for improving male functions and preparation method thereof | 广州白云山医药集团股份有限公司白云山化学制药厂 | 2024-11-12 | — | — | CN | claimed |
| CN-221731631-U | Film coating device for dapoxetine hydrochloride tablets | 山东颐正达医药科技有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-221584640-U | Fine powder recovery device for tablet pressing of dapoxetine hydrochloride | 山东颐正达医药科技有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-221542099-U | Dapoxetine hydrochloride piece partial shipment ware | 山东颐正达医药科技有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-118453529-A | Tadalafifenprodil orally disintegrating tablet and preparation method thereof | 重庆康刻尔制药股份有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-103100085-A | Pharmaceutical composition | SHANGHAI LANDISI BIOLOG MEDICAL TECHNOLOGY CO LTD | 2013-05-15 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-2490676-A2 | PHARMACEUTICAL COMPOSITIONS OF PDE-5 INHIBITORS AND DAPOXETINE | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2012-08-29 | — | — | EP | claimed |
| EP-2316435-A1 | Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2011-05-04 | — | — | EP | claimed |
| WO-2011048553-A2 | PHARMACEUTICAL COMPOSITIONS OF PDE-5 INHIBITORS AND DAPOXETINE | ABDI IBRAHIM ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2011-04-28 | — | — | WO | claimed |
| WO-2008035358-A2 | PROCESS FOR PREPARING DAPOXETINE | CADILA HEALTHCARE LIMITED (IN) | 2008-03-27 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |